MX2011008562A - Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabolicas. - Google Patents
Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabolicas.Info
- Publication number
- MX2011008562A MX2011008562A MX2011008562A MX2011008562A MX2011008562A MX 2011008562 A MX2011008562 A MX 2011008562A MX 2011008562 A MX2011008562 A MX 2011008562A MX 2011008562 A MX2011008562 A MX 2011008562A MX 2011008562 A MX2011008562 A MX 2011008562A
- Authority
- MX
- Mexico
- Prior art keywords
- cardiotrophin
- treatment
- metabolic diseases
- insulin
- hyperglycaemias
- Prior art date
Links
- 102100028892 Cardiotrophin-1 Human genes 0.000 title abstract 3
- 108010041776 cardiotrophin 1 Proteins 0.000 title abstract 3
- 208000030159 metabolic disease Diseases 0.000 title 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000002891 anorexigenic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000001842 enterocyte Anatomy 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 230000001235 sensitizing effect Effects 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200900396 | 2009-02-12 | ||
| PCT/ES2010/070072 WO2010092218A2 (es) | 2009-02-12 | 2010-02-10 | Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabólicas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011008562A true MX2011008562A (es) | 2011-09-09 |
Family
ID=42562119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011008562A MX2011008562A (es) | 2009-02-12 | 2010-02-10 | Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabolicas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110293562A1 (enExample) |
| EP (1) | EP2397152B1 (enExample) |
| JP (1) | JP2012517459A (enExample) |
| CN (1) | CN102316892B (enExample) |
| AU (1) | AU2010212794A1 (enExample) |
| BR (1) | BRPI1008415A2 (enExample) |
| CA (1) | CA2750074A1 (enExample) |
| ES (1) | ES2493618T3 (enExample) |
| MX (1) | MX2011008562A (enExample) |
| RU (1) | RU2011137413A (enExample) |
| WO (1) | WO2010092218A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11419916B2 (en) | 2012-09-11 | 2022-08-23 | Energesis Pharmaceuticals, Inc. | Methods and compositions for inducing differentiation of human brown adipocyte progenitors |
| US10130288B2 (en) | 2013-03-14 | 2018-11-20 | Cell and Molecular Tissue Engineering, LLC | Coated sensors, and corresponding systems and methods |
| US10405961B2 (en) | 2013-03-14 | 2019-09-10 | Cell and Molecular Tissue Engineering, LLC | Coated surgical mesh, and corresponding systems and methods |
| EP3943092B1 (en) * | 2014-02-24 | 2024-11-13 | Energesis Pharmaceuticals Inc. | Compositions for use in inducing differentiation of human brown adipocyte progenitors |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL68769A (en) | 1983-05-23 | 1986-02-28 | Hadassah Med Org | Pharmaceutical compositions containing insulin for oral administration |
| US4849405A (en) | 1984-05-09 | 1989-07-18 | Synthetic Blood Corporation | Oral insulin and a method of making the same |
| US4963526A (en) | 1984-05-09 | 1990-10-16 | Synthetic Blood Corporation | Oral insulin and a method of making the same |
| EP0179904A1 (en) | 1984-05-09 | 1986-05-07 | Medaphore Inc. | Oral insulin and a method of making the same |
| US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| US4992417A (en) | 1987-07-17 | 1991-02-12 | Mount Sinai School Of Medicine | Superactive human insulin analogues |
| US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
| US5642868A (en) | 1990-05-02 | 1997-07-01 | The United States Of America As Represented By The Secretary Of The Navy | Ceramic material |
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
| US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US5461031A (en) | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US5547929A (en) | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
| US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
| US5843866A (en) | 1994-12-30 | 1998-12-01 | Hampshire Chemical Corp. | Pesticidal compositions comprising solutions of polyurea and/or polyurethane |
| AR002976A1 (es) | 1995-03-31 | 1998-05-27 | Lilly Co Eli | Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas |
| US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
| US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
| US6153632A (en) | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
| ZA984697B (en) | 1997-06-13 | 1999-12-01 | Lilly Co Eli | Stable insulin formulations. |
| HUP0101250A3 (en) | 1998-01-29 | 2006-06-28 | Poly Med Inc Anderson | Absorbable microparticles |
| AU5027299A (en) | 1998-07-31 | 2000-02-28 | Novo Nordisk A/S | Use of glp-1 and analogues for preventing type ii diabetes |
| US6211144B1 (en) | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
| EP1539930A4 (en) * | 2002-07-29 | 2006-08-09 | Es Cell Int Pte Ltd | METHOD IN MULTIPLE STAGES OF DIFFERENTIATION OF POSITIVE INSULIN-SENSITIVE CELLS, GLUCOSE |
| WO2005053728A2 (de) * | 2003-12-01 | 2005-06-16 | Xantos Biomedicine Ag | Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik |
| GT200600046A (es) * | 2005-02-09 | 2006-09-25 | Terapia de combinacion | |
| JP2008533101A (ja) * | 2005-03-17 | 2008-08-21 | ノボ ノルディスク アクティーゼルスカブ | 肥満の治療において使用するための化合物 |
| WO2007093363A1 (en) | 2006-02-15 | 2007-08-23 | Sanofi-Aventis | Novel azacycly-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments |
-
2010
- 2010-02-10 CN CN201080009256.9A patent/CN102316892B/zh not_active Expired - Fee Related
- 2010-02-10 BR BRPI1008415-0A patent/BRPI1008415A2/pt not_active IP Right Cessation
- 2010-02-10 MX MX2011008562A patent/MX2011008562A/es not_active Application Discontinuation
- 2010-02-10 US US13/201,431 patent/US20110293562A1/en not_active Abandoned
- 2010-02-10 WO PCT/ES2010/070072 patent/WO2010092218A2/es not_active Ceased
- 2010-02-10 AU AU2010212794A patent/AU2010212794A1/en not_active Abandoned
- 2010-02-10 CA CA2750074A patent/CA2750074A1/en not_active Abandoned
- 2010-02-10 EP EP10710061.2A patent/EP2397152B1/en active Active
- 2010-02-10 ES ES10710061.2T patent/ES2493618T3/es active Active
- 2010-02-10 RU RU2011137413/15A patent/RU2011137413A/ru unknown
- 2010-02-10 JP JP2011549615A patent/JP2012517459A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN102316892B (zh) | 2014-06-04 |
| JP2012517459A (ja) | 2012-08-02 |
| EP2397152A2 (en) | 2011-12-21 |
| WO2010092218A3 (es) | 2010-11-18 |
| RU2011137413A (ru) | 2013-03-20 |
| CN102316892A (zh) | 2012-01-11 |
| ES2493618T3 (es) | 2014-09-12 |
| EP2397152B1 (en) | 2014-05-28 |
| CA2750074A1 (en) | 2010-08-19 |
| US20110293562A1 (en) | 2011-12-01 |
| BRPI1008415A2 (pt) | 2018-02-27 |
| AU2010212794A1 (en) | 2011-08-11 |
| WO2010092218A2 (es) | 2010-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009011359A (es) | Derivados de pirimidinona y sus metodos de uso. | |
| EA201300550A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| WO2011127304A3 (en) | Methods of treating an overweight subject | |
| MX2009011358A (es) | Derivados de pirimidinona y metodos para su uso. | |
| MX2010004450A (es) | Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119. | |
| UA100008C2 (ru) | Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и фармацевтической композицией, которая их содержит | |
| MX2009009416A (es) | Derivados de bencimidazol y sus metodos de uso. | |
| ATE477819T1 (de) | Verwendung von organischen verbindungen | |
| MX2011008562A (es) | Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabolicas. | |
| MX2015008079A (es) | Agonista duales de glp1/gip o trigonales de glp1/gip/glucagon. | |
| MY176863A (en) | Ibat inhibitors for treatment of metabolic disorders and related conditions | |
| CY1117603T1 (el) | Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2 | |
| MX2009003658A (es) | Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa. | |
| GB201101459D0 (en) | Novel compounds and thier effects on fedding behaviour | |
| GB2462947A (en) | Fatty Acid Oxidation Inhibitors Treating Hyperglycemia and Related Disorders. | |
| EP3695841A3 (en) | Ship inhibition to combat obesity | |
| MX2010001866A (es) | Derivados de azoloarina, metodo para su produccion, productos farmaceuticos que contienen estos compuestos y su uso. | |
| Hilberg | Physical activity in the prevention of cardiovascular diseases. Epidemiology and mechanisms | |
| MX2011012778A (es) | Nuevos derivados de ciclopentano. | |
| MY156174A (en) | 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity | |
| TW201129573A (en) | Pyrimidine ether derivatives and methods of use thereof | |
| WO2010007085A3 (en) | Use of gcn5 inhibitors in medicine | |
| TW200640842A (en) | Derivatives of aminobutanoic acid inhibiting CPT | |
| DE602004018352D1 (de) | Therapeutische anwendungen für c-peptid | |
| Lai et al. | B27 MITOCHONDRIA AND METABOLIC DYSFUNCTION IN PULMONARY HYPERTENSION: Ampk Activation By Nitrite And Metformin Increases Glut4-Mediated Glucose Uptake And Normalizes Pulmonary Venous Hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: PROYECTO DE BIOMEDICINA CIMA, S.L. |
|
| FA | Abandonment or withdrawal |